Relação entre os sinais clínicos neurológicos e os achados tomográficos de 20 cães com suspeita de neoplasia intracraniana

Pós-graduação em Medicina Veterinária - FMVZ

Imunomarcação de micrometástases de neoplasias mamárias espontâneas em linfonodos de cadelas por meio do receptor CD44

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Inibição do receptor tipo-1 ativado por protease (PAR¹) na doença e reparo periodontal

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Caracterização da resposta imune celular em mulheres com câncer de ovário

Pós-graduação em Ginecologia, Obstetrícia e Mastologia - FMB

Avaliação da atividade antiinflamatória, antitumoral e antiangiogênica de compostos isolados da planta Alchornea glandulosa e de fungos endofíticos a ela relacionados

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Iogurte de soja como coadjuvante no tratamento de câncer de mama

Pós-graduação em Biociências e Biotecnologia Aplicadas à Farmácia - FCFAR

Estudo anátomo-clínico do linfonodo sentinela no câncer de mama

Pós-graduação em Ginecologia, Obstetrícia e Mastologia - FMB

Efeitos das dietas em Ômega-3 OU Ômega-6 na expressão gênica de neoplasias mamárias de ratas Sprague-Dawley sob o tratamento com tomoxifeno

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Desenvolvimento e caracterização físico-química e biofarmacêutica de nano e microemulsões lipídicas de uso intravenoso contendo metildiidrojasmonato

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Transformadas integrais, modelagem fracionária e o sistema de Lotka-Volterra

Pós-graduação em Biometria - IBB

Avaliação da angiogênese em resposta ao tratamento com melatonina no câncer de mama: estudo in vitro e in vivo

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Efeito da curcumina na angiogênese em modelo experimental de câncer de mama

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Oral squamous carcinoma cells secrete RANKL directly supporting osteolytic bone loss

Objective: Local invasion of bone is a frequent complication of oral squamous cell carcinoma (OSCC). Development of these osteolytic lesions is mediated by osteoclasts. Receptor activation of NF-kappa B ligand (RANKL) signaling, counteracted by osteoprotegerin (OPG), regulates osteoclastogenesis. Previous studies in rodent models have demonstrated that inhibition of RANKL decreases tumor growth and lesions within bone. However, the contributory role of OSCC cells to this disease process has yet to be defined.Methods: RANKL expression was assessed in a panel of OSCC cell lines by qPCR, flow cytometry, and ELISA. Induction of osteoclastogenesis was assessed by co-culture with macrophages or with OSCC-derived conditioned medium. In an animal model of bone invasion, nude mice were injected intratibially with UMSCC-11B cells expressing a RANKL luciferase promoter to detect tumor-derived RANKL activity. Osteolytic lesions were analyzed by X-ray, micro-CT, and histological methods. RANKL expression was assessed in human OSCC tissues by immunohistochemistry.Results: We demonstrated that OSCCs express varied levels of all RANKL isoforms, both membrane-bound and soluble RANKL. Both co-culture and treatment with OSCC-conditioned media induced osteoclastogenesis. In mice, we demonstrated human RANKL promoter activity during bone invasion. Over the course of the experiment, animals suffered osteolytic lesions as RANKL-driven luciferase expression increased with time. After 8 weeks, human-derived RANKL was detected in areas of bone resorption by immunohistochemistry. Similar epithelial RANKL expression was detected in human OSCC tissues.Conclusion: These data demonstrate the ability of OSCCs to produce RANKL, directly altering the tumor microenvironment to increase osteoclastogenesis and mediate local bone invasion. (C) 2012 Elsevier Ltd. All rights reserved.

Wavelets based Algorithm for the Evaluation of Enhanced Liver Areas

Hepatocellular carcinoma (HCC) is a primary tumor of the liver. After local therapies, the tumor evaluation is based on the mRECIST criteria, which involves the measurement of the maximum diameter of the viable lesion. This paper describes a computed methodology to measure through the contrasted area of the lesions the maximum diameter of the tumor by a computational algorithm 63 computed tomography (CT) slices from 23 patients were assessed. Non-contrasted liver and HCC typical nodules were evaluated, and a virtual phantom was developed for this purpose. Optimization of the algorithm detection and quantification was made using the virtual phantom. After that, we compared the algorithm findings of maximum diameter of the target lesions against radiologist measures. Computed results of the maximum diameter are in good agreement with the results obtained by radiologist evaluation, indicating that the algorithm was able to detect properly the tumor limits A comparison of the estimated maximum diameter by radiologist versus the algorithm revealed differences on the order of 0.25 cm for large-sized tumors (diameter > 5 cm), whereas agreement lesser than 1.0cm was found for small-sized tumors. Differences between algorithm and radiologist measures were accurate for small-sized tumors with a trend to a small increase for tumors greater than 5 cm. Therefore, traditional methods for measuring lesion diameter should be complemented with non-subjective measurement methods, which would allow a more correct evaluation of the contrast-enhanced areas of HCC according to the mRECIST criteria.

Low expression of sodium iodide symporter identifies aggressive thyroid tumors

A decreased radioiodine uptake is frequently detected in differentiated thyroid carcinomas (DTC) and is associated with high recurrence rate and reduced survival. We investigated the correlation between NIS mRNA expression levels in the primary tumor and patient outcome using a quantitative real-time RT-PCR method. NIS expression was decreased in 17 DTC (21.04 +/- 39.66 pg Eq) compared to four autoimune thyroid disease (180.51 +/- 92.63 pg Eq) and 14 normal tissues (75.71 +/- 66.98 pg Eq) (p < 0.0001). The 17 thyroid differentiated carcinoma patients were submitted to surgery complemented by radioiodine ablation and had at least 24 months of follow-up, under levothyroxine continued suppressive therapy. According to their outcome, we could characterize a group of papillary carcinoma patients with aggressive carcinomas, whose NIS mRNA levels were markedly lower than a group with non-aggressive carcinomas (0.62 +/- 0.79 versus 54.87 +/- 53.79: p < 0.005). We suggest that the quantification of NIS mRNA relative levels in the primary tumor may predict poor outcome. (C) 2003 Elsevier Ireland Ltd. All rights reserved.